Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: Systematic review and meta-analysis

Retina

Volumn 33, Issue 7, 2013, Pages 1375-1392

  Wang, Erqian ^a   Chen, Youxin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ENDOPHTHALMITIS; FOVEOSCHISIS; HUMAN; INTRAOCULAR PRESSURE; META ANALYSIS; MYOPIA; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA TEAR; RETINAL THICKNESS; REVIEW; SCORING SYSTEM; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL (TOPIC); COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; HUMANS; INTRAVITREAL INJECTIONS; MYOPIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879965271     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31827d260a     Document Type: Review

References (122)

1. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103:1241-1244.
2. Pece A, Brancato R, Avanza P, et al. Laser photocoagulation of choroidal neovascularization in pathologic myopia: longterm results. Int Ophthalmol 1994;18:339-344.
3. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 2000;118:344-350.
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin, 1 year results of a randomized clinical trial - VIP report No. 1. Ophthalmology 2001;108:841-852.
5. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003;110:667-673.
6. Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006;26:960-963.
7. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006;26:1093-1094.
8. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495-525.
9. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29:1062-1066.
10. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-1305.
11. Lai TY. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina 2012;32:1443-1445.
12. Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010;128:437-442.
13. Wakabayashi T, Ikuno Y, Gomi F, et al. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia. Am J Ophthalmol 2009;148:591-596.
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
15. Sterne JAC, Egger M, Moher D, eds. Chapter 10: addressing reporting biases. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
16. Higgins JPT, Deeks JJ, eds. Chapter 7: selecting studies and collecting data. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
17. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomized controlled trial. Am J Ophthalmol 2010;149:458-464.
18. Heier JS, Brown D, Ciulla T, et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011;118:111-118.
19. Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, et al. Myopic choroidal neovascularization. Ophthalmology 2011;118:2521-2523.
20. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012;32:1539-1546.
21. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009;148: 396-408.
22. Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010;94:864-870.
23. Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010;149:140-146.
24. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010;30:418-424.
25. Chen L, Miller JW, Vavvas D, Kim IK. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retina 2011;31:2078-2083.
26. El Matri L, Kort F, Chebil A, et al. Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population. Graefes Arch Clin Exp Ophthalmol 2011;249:1287-1293.
27. Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 2011;249:595-599.
28. Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina 2011;31:880-886.
29. Dethorey G, Leveziel N, Lalloum F, et al. Efficacy of intravitreal injections of ranibizumab compared to visudyne phototherapy in myopic choroidal neovascularization associated with high myopia. J Fr Ophtalmol 2012;35:106-112.
30. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 2012;26:1004-1011.
31. Matsuo M, Honda S, Matsumiya W, et al. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. Eur J Ophthalmol 2012;22:210-215.
32. Niwa Y, Sawada O, Miyake T, et al. Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Res 2012;47:135-140.
33. Ruiz-Moreno JM, Montero JA, Arias L, et al. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta Ophthalmol 2012;90:e82-e83.
34. Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-2196.
35. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27:707-712.
36. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
37. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008;92: 1035-1039.
38. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
39. Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-154.
40. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93.
41. Hayashi K, Ohno-Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009;247:609-618.
42. Konstantinidis L, Mantel I, Pournaras J-AC, et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:311-318.
43. Mones JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 2009;23:1275-1280.
44. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (Lond) 2009;23:334-338.
45. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab. Br J Ophthalmol 2009;93:1693-1694.
46. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
47. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye (Lond) 2009;23:2042-2045.
48. Yodoi Y, Tsujikawa A, Nakanishi H, et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009; 147:816-824.
49. Cornut PL, Poli M, Feldman A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmol 2010;33:327-333.
50. Gharbiya M, Allievi F, Conflitti S, et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010;161: e87-e93.
51. Lalloum F, Souied EH, Bastuji-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010;30:399-406.
52. Loh BK, Lee SY, Cheng J, et al. Intravitreal bevacizumab for the treatment of myopic choroidal neovascularisation in an Asian population. Ann Acad Med Singapore 2010;39:493-494.
53. Ouhadj O, Bouarfa A, Akel S, et al. Intravitreal ranibizumab injections for the treatment of choroidal neovascularization complicating high myopia. J Fr Ophtalmol 2010;33:649-654.
54. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010;248:937-941.
55. Scupola A, Tiberti AC, Sasso P, et al. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results. Retina 2010;30:739-747.
56. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010;30:407-412.
57. Calvo-Gonzalez C, Reche-Frutos J, Donate J, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 2011;151:529-534.
58. Desco MC, Mataix J, Garcia-Pous M, et al. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up. Retina 2011; 31:475-481.
59. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina 2011;31:1841-1847.
60. Salman AG. Intravitreal bevacizumab for pediatric exudative retinal diseases. Saudi J Ophthalmol 2011;25:193-197.
61. Vadala M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 2011;95:657-661.
62. Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 2012;6:837-844.
63. Gharbiya M, Cruciani F, Parisi F, et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2012;96:1068-1072.
64. Hayashi K, Shimada N, Moriyama M, et al. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012;32:687-695.
65. Troutbeck R, Bunting R, van Heerdon A, et al. Ranibizumab therapy for choroidal neovascularization secondary to nonage- related macular degeneration causes. Clin Experiment Ophthalmol 2012;40:67-72.
66. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160.
67. Chang LK, Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945.
68. Kerimov MI, Abdullayeva EA, Aliyev KD, Shahmaliyeva AM. Estimation of efficacy of intravitreal avastin injection for choroidal neovascularization. Azerbaijan Med J 2008;60-63.
69. Rensch F, Spandau UHM, Schlichtenbrede F, et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008;39:182-185.
70. Rhéaume MA, Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008;43:576-580.
71. Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:2187-2193.
72. Dithmar S, Schaal KB, Hoh AE, et al. Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia [in German]. Ophthalmologe 2009;106:527-530.
73. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
74. Lai TYY, Chan W-M, Liu DTL, Lam DSC. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29:750-756.
75. Qian J, Xu WQ, Wang WJ, et al. Evaluation of intravitreal injection of bevacizumab for treatment of choroidal neovascularization by optical coherence tomography. J Shanghai Jiaotong Univ (Med Sci) 2009;29:188-191.
76. Spielberg L, Leys A. Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results. Bull Soc Belge Ophtalmol 2009;312:17-27.
77. Torron C, Egea C, Ferrer E, et al. Ranibizumab as treatment for myopic choroidal neovascularization [in Spanish]. Arch Soc Esp Oftalmol 2009;84:507-514.
78. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 2010;30:1432-1440.
79. Coppens G, Angulo Bocco MI, Spielberg L, Leys A. Intravitreal bevacizumab for myopic choroidal neovascularization: 1-year and 2-year results. Bull Soc Belge Ophtalmol 2010; 315:39-45.
80. Han DP, McAllister JT, Weinberg DV, et al. Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond) 2010; 24:713-716.
81. Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol 2010;45:239-242.
82. Moussa S, Ansari-Shahrezaei S, Smretschnig E, et al. Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2010;248:1087-1090.
83. Ozdek S, Sekeryapan B, Ekici F, Hasanreisoglu B. Management of choroidal neovascularization in pathologic myopia: combined therapy. Retina-Vitreus 2010;18:197-202.
84. Rotsos T, Sagoo MS, daCruz L, et al. Intravitreal anti-VEGF treatment in eyes with combined choroidal neovascularisation and vitreomacular traction syndrome. Br J Ophthalmol 2010; 94:1205-1210.
85. Ruiz-Moreno JM, Montero JA, Arias L, et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010;30: 1609-1615.
86. Varano M, Tedeschi M, Oddone F, et al. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. Retina 2010;30:413-417.
87. Voykov B, Gelisken F, Inhoffen W, et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010;248:543-550.
88. Chen CH, Wu PC, Chen YJ, et al. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. J Ocul Pharmacol Ther 2011;27:395-400.
89. Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 2011;31:1525-1533.
90. Gedik Oguz Y, Batioglu F, Ozmert E. The results of intravitreal ranibizumab injection for choroidal neovascularization from causes other thanage-related macular degeneration. Retina-Vitreus 2011;19:231-236.
91. Hefner L, Riese J, Gerding H. Results of ranibizumab treatment for choroidal neovascularization secondary to pathological myopia [in German]. Klin Monbl Augenheilkd 2011;228:284-287.
92. Kuo JZ, Ong FS, Yeung L, et al. Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization. Retina 2011;31: 1835-1840.
93. Liebbe Gallardo JL. Bevacizumab en el tratamiento de la neovascularización coroidea miópica. Arch Chil Oftalmol 2011;66:41-48.
94. Lorenzo D, Arias L, Alcubierre R, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up. Ophthalmologica 2011; 226:103-109.
95. Meyer CH, Michels S, Rodrigues EB, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011;89:70-75.
96. Nakanishi H, Tsujikawa A, Yodoi Y, et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011;25: 375-381.
97. Qureshi F, Saeed MU, Kamal A. Primary intravitreal ranibizumab for myopic choroidial neovascularisation. Semin Ophthalmol 2011;26:52-54.
98. Rishi P, Rishi E, Venkataraman A, et al. Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia. Indian J Ophthalmol 2011;59:242-246.
99. Shimada N, Ohno-Matsui K, Hayashi K, et al. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 2011;55:378-382.
100. Franqueira N, Cachulo ML, Pires I, et al. Long-term followup of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 2012;227:39-44.
101. Lavric A, Urbancic M, Kraut A, et al. Treatment of choroidal neovascularisation in highly myopic eyes. Zdrav Vestn 2012; 81:67.
102. Oishi A, Yamashiro K, Tsujikawa A, et al. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2012 [Epub ahead of print].
103. Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 2012;47:28-33.
104. Uemoto R, Nakasato-Sonn H, Kawagoe T, et al. Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2012;250:989-997.
105. Wu TT, Kung YH. The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther 2012;28:129-133.
106. Yoon JU, Kim YM, Lee SJ, et al. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Retina 2012;32:949-955.
107. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17: 620-626.
108. Hu YQ, Chen QS, Fang M, Yang X. Clinical investigation of photodynamic therapy and intravitreal Avastin for choroidal neovascularization due to pathologic myopia. Int Eye Sci 2012;12:1063-1065.
109. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 2007;245:903-905.
110. Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol 2007;21:185-187.
111. Figurska M, Stankiewicz A. Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization - cases report [in Polish]. Klin Oczna 2008;110:387-391.
112. Neri P, Mariotti C, Mercanti L, et al. Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 2008;28:425-427.
113. Amselem L, Diaz-Llopis M, Garcia-Delpech S, et al. Papulopustular eruption after intravitreal bevacizumab (Avastin). Acta Ophthalmol 2009;87:110-111.
114. Barkmeier AJ, Oz O, Ernst BI, Akduman L. Regression of choroidal neovascularization secondary to pathologic myopia after intravitreal injection of bevacizumab. Retina-Vitreus 2009;17:222-224.
115. Kumaran N, Sim DA, Tufail A. Long-term remission of myopic choroidal neovascular membrane after treatment with ranibizumab: a case report. J Med Case Rep 2009;3:84.
116. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia- Feijoo J. Early neovascular bridging of choroidal neovascularization after ranibizumab treatment. Graefes Arch Clin Exp Ophthalmol 2009;247:1427-1430.
117. Sayanagi K, Ikuno Y, Soga K, et al. Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol 2009;87:460-463.
118. Chhablani JK. Combined photodynamic therapy and intravitreal bevacizumab as treatment for nonresponsive myopic choroidal neovascularization. Oman J Ophthalmol 2010;3:159-160.
119. Petrou P, Georgalas I, Giavaras G, et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 2010;88:e136.
120. Wu Z, Huang J, Sadda S. Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann Acad Med Singapore 2010;39:143-145.
121. Nor-Masniwati S, Shatriah I, Zunaina E. Single intravitreal ranibizumab for myopic choroidal neovascularization. Clin Ophthalmol 2011;5:1079-1082.
122. Introini U, Casalino G, Cardani A, et al. Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J Ocul Pharmacol Ther 2012;28:553-555.